<DOC>
	<DOC>NCT02134210</DOC>
	<brief_summary>This is a two part study comparing CHS-0214 to Enbrel in patients with chronic plaque PsO who have not yet received any biologic therapy for any indication (other than insulin or hormones).</brief_summary>
	<brief_title>Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)</brief_title>
	<detailed_description>Pt. 1 is a 12-week randomized, double-blind, active-control, parallel-group, multi-center global study. The primary end point is 75% improvement from baseline according to the Psoriasis Area and Severity Index (PASI-75). Comparing CHS-0214 to Enbrel for efficacy and safety at a dosage of 50mg subcutaneous (Sc) twice weekly. Pt. 2 is a 40-week randomized, double-blind, active-control, parallel-group, multi-center global study where CHS-0214 and Enbrel dosage is reduced to 50mg Sc weekly for maintenance.</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Male or female adults PsO diagnosis for 6 months Active disease: PASI greater than or equal to 12, Physician's Static Global Assessment (PSGA) score greater than or equal to 3 (based on a scale or 05), Body Surface Area (BSA) involved with PsO greater than or equal to 10% Dermatology Life Quality Index (DQLI) greater than or equal to 10 Previously received phototherapy or systemic nonbiologic therapy for PsO Forms of Psoriasis other than PsO Drug induced Psoriasis Positive QuantiFERONtuberculosis (TB) Gold Test Presence of significant comorbid conditions Chemistry and hematology values outside protocol specified range Major systemic infections</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>PsO</keyword>
</DOC>